Janux Therapeutics and Merck & Co. (NYSE:MRK) have entered a license and strategic collaboration agreement to discover, develop as well as commercialize next-gen T cell engager immunotherapies for cancer treatment. Merck to pay Janux $550.5 upfront payment following a collaboration agreement The collaboration aims to leverage Janux’s Novel Tumor Activated […]
Tag: Merck & Co.
Merck & Co. (NYSE:MRK) is cashing in on the meteoric rise of Moderna Inc. (NASDAQ:MRNA) in 2020 after the pharmaceutical giant dumped its equity stake in Moderna. Since the beginning of this year, Moderna, which is developing a potential COVID-19 vaccine, has gained over 620%. Merck sells its stake in […]